Journal of the Medical Research Institute-Alexandria University. 2003; 24 (2 Supp.): 82-90
in English
| IMEMR
| ID: emr-62796
ABSTRACT
This study included 40 patients with histopathologically proved advanced stages III and IV ovarian carcinoma according to 1998 criteria of International Federation of Gynecology and Obstetrics [FIGO] staging system. Patients were divided into two groups Group I a prospectively studied group of 20 previously untreated patients, seen during the period from December 1999 to December 2000, who received cisplatin [100mg/m[2]] day I and gemcitabine [1250mg/m[2]] day and day 8 and the cycle was repeated every 21 days. Group II a retrospectively 20 patients, fulfilling the same eligibility criteria, who received cisplatin [100mg/m[2]] and cyclophosphamide [750mg/m[2]], both in day I and the cycle was repeated every 21 days. All patients in both groups received a total of six courses of treatment and the response was determined by clinical examination as well as pelvi-abdominal ultrasound, and pelvi-abdominal computed tomography. Complete response was achieved in 35% of cases in group I vs 15% in group II, while partial response was obtained in 35% in both groups. There were no statistical significant difference between overall response rate [O.R.R] in both groups [X2 = 3.86, P 0.277]. Patients who received gemcitabine/ cisplatin combination chemotherapy showed less anemia and less renal toxicity with better tolerance than the cyclophosphamide / cisplatin arm. There were no statistical significant difference between overall survival [O.S] in both arms, however the progression free survival [P.F.S] was better in group I and reached the level of significance compared to group II [P=0.03]
Search on Google
Index:
IMEMR (Eastern Mediterranean)
Main subject:
Pelvic Neoplasms
/
Biomarkers, Tumor
/
Tomography, X-Ray Computed
/
Survival Rate
/
Follow-Up Studies
/
Cisplatin
/
CA-125 Antigen
/
Drug Combinations
/
Neoplasm Staging
/
Antimetabolites, Antineoplastic
Limits:
Female
/
Humans
Language:
English
Journal:
J. Med. Res. Inst.-Alex. Univ.
Year:
2003
Similar
MEDLINE
...
LILACS
LIS